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Résumé en
anglais
PURPOSE: To assess the outcome of esophageal cancer according to therapeutic
strategy.
PATIENTS AND METHODS: One-hundred and twenty patients with esophageal
cancer treated by an association of radiotherapy and chemotherapy and possibly
surgery, between 2004 and 2010, were retrospectively studied. The first site of
relapse was classified as follows: local (tumour), locoregional (tumour and/or nodal:
celiac, mediastinal, sus-clavicular) or metastatic.
RESULTS: With a 15.7-months (1.4-62) median follow-up, there were 89 deaths and
79 recurrences. Three types of treatments were performed: 50Gy exclusive
chemoradiotherapy (47 patients) or 50 to 65Gy exclusive chemoradiotherapy (44
patients) or chemoradiotherapy followed by surgery (27 patients). The local first
relapse was as much frequent as distant relapse (50 patients). With a-5cm margin
up and down to the tumour, there was only one nodal relapse. Two-year survival was
39.5% (95% confidence interval [IC]: 30.5-40.8) and relapse-free survival was 26.5%
(CI: 18.6-35). Multivariate analysis revealed that treatment type and disease stage
had a significant impact on survival, relapse-free survival and locoregional control.
Compared to exclusive chemoradiotherapy, surgery improved locoregional control
(40.2 versus 8.7 months, P=0.0004) but in a younger population. Despite
postoperative mortality, the gain was maintained for distance relapse-free survival
(40.2 versus 10 months, P=0.0147) and overall survival (29.3 versus 14.2 months,
P=0.0088). Compared to 50Gy chemoradiotherapy, local control was improved if
high dose chemoradiotherapy was performed (13.8 versus 7.5 months, P=0.05) but
not overall survival (14.0 versus 15.4 months, P=0.24).
CONCLUSION: More than one-third relapse is local. Locoregional control is better
with high dose chemoradiotherapy. In this study, surgery performed in selected
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